Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9666734 | 0.96 | ALDH1A1 (0.45) | CYP2C19LMNAALDH1A1POLBTP53 | |
| SCHEMBL56169 | 0.81 | YTHDC1 (0.46) | LMNAALDH1A1POLBYTHDC1CYP4F2 | |
| SCHEMBL16809888 | 0.81 | CYP2C19 (0.39) | CYP2C19LMNAALDH1A1POLBTP53 | |
| SCHEMBL16793799 | 0.80 | CYP4F2 (0.42) | LMNAALDH1A1POLBYTHDC1CYP4F2 | |
| SCHEMBL29705484 | 0.80 | CYP4F2 (0.42) | LMNAALDH1A1POLBYTHDC1CYP4F2 | |
| SCHEMBL31041669 | 0.80 | RET (0.38) | CYP2C19LMNAALDH1A1POLBTP53 | |
| SCHEMBL2075668 | 0.80 | ABL1 (0.47) | LMNATP53PI4KBMAPT | |
| SCHEMBL19464241 | 0.79 | LMNA (0.39) | CYP2C19LMNAALDH1A1POLBTP53 | |
| SCHEMBL29705852 | 0.79 | LMNA (0.39) | CYP2C19LMNAALDH1A1POLBTP53 | |
| SCHEMBL19463518 | 0.79 | ALDH1A1 (0.48) | CYP2C19LMNAALDH1A1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| EP-3868751-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| EP-3868751-B1 | 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116249531-A | Compositions and methods for activating pyruvate kinase | 密执安大学评议会 | 2023-06-09 | — | — | CN | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230121489-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20230121489-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2023-04-20 | — | — | US | disclosed |
| EP-4071150-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | Redx Pharma Plc (GB) | 2022-10-12 | — | — | EP | disclosed |
| US-11459326-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | REDX PHARMA PLC (GB) | 2022-10-04 | — | — | US | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | THOMPSON WAYNE (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005019221-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019221-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019222-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019222-A1 | 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-RE35072-E | Cardiotonic agents and antiarrhythmic agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-10-24 | — | — | US | disclosed |
| US-5001127-A | 4-substituted pyrazolo[3,4-d]pyrimidine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-03-19 | — | — | US | disclosed |
| US-4885300-A | CARDIOTONIC AND ANTIARRHYTHMIA AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0331510-A2 | 4-Substituted pyrazolo[3,4-d]pyrimidine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459326-B2 | N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors | WNT1, WNT3, CTNNB1 | CYP2C19 1644/4885LMNA 36/4885ALDH1A1 974/4885 |
| US-20230121489-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS | WNT1, WNT3, CTNNB1 | CYP2C19 1644/4885LMNA 36/4885ALDH1A1 974/4885 |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | CYP2C19 3671/4885LMNA 1036/4885ALDH1A1 1403/4885 |
| US-20050054658-A1 | 4-Cycloalkylaminopyrazolo pyrimidine NMDA/NR2B antagonists | GRIN2B, GRIN1, GRIN2A | CYP2C19 689/4885LMNA 4619/4885ALDH1A1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.